ArticleLeukemia2009
Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo.
Article in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.Haematologica · 2015Trial
- Single cell transcriptional evolution of myeloid leukemia of Down syndrome.Nature communications · 2026Article
- FHL2 deficiency aggravates Candida albicans infection through decreased myelopoiesis.Science China. Life sciences · 2025Article
- Effects of the FHL2 gene on the development of subcutaneous and intramuscular adipocytes in goats.BMC genomics · 2024Article
- How (Epi)Genetic Regulation of the LIM-Domain Protein FHL2 Impacts Multifactorial Disease.Cells · 2021Review
- Mechanosensing through Direct Binding of Tensed F-Actin by LIM Domains.Developmental cell · 2020Article
- Early Dendritic Morphogenesis of Adult-Born Dentate Granule Cells Is Regulated by FHL2.Frontiers in neuroscience · 2020Article
- Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia.Cancer gene therapy · 2019Article
- miR-9 upregulation leads to inhibition of erythropoiesis by repressing FoxO3.Scientific reports · 2018Article
- FHL2 Regulates Natural Killer Cell Development and Activation duringFrontiers in immunology · 2017Article
- Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.Oncogene · 2016Article
- A Transcriptomic Signature of Mouse Liver Progenitor Cells.Stem cells international · 2016Article
- Article
- LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis.Molecular and cellular biology · 2013Article
- Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Activation of Wnt/β-catenin protein signaling induces mitochondria-mediated apoptosis in hematopoietic progenitor cells.The Journal of biological chemistry · 2012Article
- FHL2 protein is a novel co-repressor of nuclear receptor Nur77.The Journal of biological chemistry · 2011Article
- FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia.Blood cancer journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
FHL2 is a multifunctional LIM domain protein that acts as a transcriptional modulator mediating proliferation and apoptosis in a tissue-specific manner. Upregulation of FHL2 has been detected in a variety of cancers. We demonstrate that upregulation of FHL2 is associated with a subset of acute myeloid leukemia with a characteristic gene-expression signature, and abnormalities of chromosome 5. In mice, expression of endogenous Fhl2 is downregulated coordinately during the differentiation of hematopoietic cells. Upregulation of FHL2 enhances proliferation of myeloid progenitor cells, and serial-replating efficiency of hematopoietic cells in vitro. Chimeric mice with enforced expression of FHL2 in bone marrow cells, are characterized by an expanded pool of myeloid progenitor cells, enhanced granulopoiesis and megakaryocytopoiesis. In addition, enhanced expression of FHL2 promotes cell-cycle entry of myeloid progenitor cells and increases the frequency of apoptosis of bone marrow cells in vivo. These results raise the possibility that deregulation of FHL2 contributes to the development of human myeloid disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.